CN112714646A - 蛋白酪氨酸激酶6(ptk6)降解/破坏化合物和使用方法 - Google Patents

蛋白酪氨酸激酶6(ptk6)降解/破坏化合物和使用方法 Download PDF

Info

Publication number
CN112714646A
CN112714646A CN201980058356.1A CN201980058356A CN112714646A CN 112714646 A CN112714646 A CN 112714646A CN 201980058356 A CN201980058356 A CN 201980058356A CN 112714646 A CN112714646 A CN 112714646A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
membered
heterocyclyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980058356.1A
Other languages
English (en)
Chinese (zh)
Inventor
金剑
H·艾瑞斯
刘静
熊燕
J·拜尔里
S·托米塔
J·P·胡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of CN112714646A publication Critical patent/CN112714646A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980058356.1A 2018-07-05 2019-07-03 蛋白酪氨酸激酶6(ptk6)降解/破坏化合物和使用方法 Pending CN112714646A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862694118P 2018-07-05 2018-07-05
US62/694,118 2018-07-05
PCT/US2019/040507 WO2020010204A1 (en) 2018-07-05 2019-07-03 Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use

Publications (1)

Publication Number Publication Date
CN112714646A true CN112714646A (zh) 2021-04-27

Family

ID=69060000

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980058356.1A Pending CN112714646A (zh) 2018-07-05 2019-07-03 蛋白酪氨酸激酶6(ptk6)降解/破坏化合物和使用方法

Country Status (6)

Country Link
US (1) US20230070613A1 (https=)
EP (1) EP3817745A4 (https=)
JP (1) JP2021529807A (https=)
CN (1) CN112714646A (https=)
CA (1) CA3105121A1 (https=)
WO (1) WO2020010204A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113354619A (zh) * 2021-06-24 2021-09-07 皖南医学院 一种靶向泛素化降解酪氨酸酶的化合物及其制备方法和应用
CN113956233A (zh) * 2021-10-22 2022-01-21 南方医科大学 一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190084063A (ko) 2016-10-28 2019-07-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
EP3810145A4 (en) 2018-06-21 2022-06-01 Icahn School of Medicine at Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
JP7503851B2 (ja) 2019-05-06 2024-06-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CA3242835A1 (en) * 2022-01-07 2023-07-13 Dana-Farber Cancer Institute, Inc. Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120131624A (ko) * 2011-05-26 2012-12-05 연세대학교 산학협력단 Ｐｔｋ 6의 활성 억제용 조성물 및 이를 이용한 암 예방 및 치료용 조성물
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
CN107849050A (zh) * 2015-05-21 2018-03-27 爱丁堡大学董事会 化合物
US20180134684A1 (en) * 2015-07-07 2018-05-17 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102668696B1 (ko) * 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP3083602A1 (en) * 2013-12-20 2016-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
RU2738833C9 (ru) * 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CN108137593B (zh) * 2015-04-21 2021-01-05 上海交通大学医学院附属瑞金医院 蛋白激酶抑制剂的制备和用途
CA2988414C (en) * 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
MX2017016325A (es) * 2015-06-22 2018-03-02 Ono Pharmaceutical Co Compuesto inhibidor de cinasa de tumor de mama (brk).
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
GB201516243D0 (en) * 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112018008918A8 (pt) * 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
EP3445765A4 (en) * 2016-04-22 2019-09-18 Dana Farber Cancer Institute, Inc. DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
ES2909234T3 (es) * 2016-12-21 2022-05-05 Ono Pharmaceutical Co Compuestos de 6-amino-7,9-dihidro-8H-purin-8-ona como inhibidores de Brk

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120131624A (ko) * 2011-05-26 2012-12-05 연세대학교 산학협력단 Ｐｔｋ 6의 활성 억제용 조성물 및 이를 이용한 암 예방 및 치료용 조성물
CN107849050A (zh) * 2015-05-21 2018-03-27 爱丁堡大学董事会 化合物
US20180134684A1 (en) * 2015-07-07 2018-05-17 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113354619A (zh) * 2021-06-24 2021-09-07 皖南医学院 一种靶向泛素化降解酪氨酸酶的化合物及其制备方法和应用
CN113354619B (zh) * 2021-06-24 2024-03-19 皖南医学院 一种靶向泛素化降解酪氨酸酶的化合物及其制备方法和应用
CN113956233A (zh) * 2021-10-22 2022-01-21 南方医科大学 一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用
CN113956233B (zh) * 2021-10-22 2023-06-06 南方医科大学 一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用

Also Published As

Publication number Publication date
WO2020010204A1 (en) 2020-01-09
US20230070613A1 (en) 2023-03-09
EP3817745A4 (en) 2022-04-06
EP3817745A1 (en) 2021-05-12
JP2021529807A (ja) 2021-11-04
CA3105121A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
US20260115297A1 (en) Heterobifunctional compounds as degraders of hpk1
EP3841098B1 (en) Tropomyosin receptor kinase (trk) degradation compounds and methods of use
CN112714646A (zh) 蛋白酪氨酸激酶6(ptk6)降解/破坏化合物和使用方法
US12110295B2 (en) WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use
EP3762381B1 (en) Bivalent agents comprising a serine threonine kinase (akt) ligand covalently linked to a degradation/disruption moiety for the treatment of cancer
US20210261538A1 (en) Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
US20210283261A1 (en) Compositions and Methods for Treating ALK-Mediated Cancer
WO2022086937A1 (en) Heterobifunctional compounds as degraders of enl
WO2022165185A9 (en) Cancer-selective target degradation by targeting group caged protacs
US11969472B2 (en) Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US20250136589A1 (en) Heterobifunctional compounds as hpk1 degraders
HK40045723A (en) Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210427

WD01 Invention patent application deemed withdrawn after publication